DNA polymerase alpha Inhibitors
1 drugsAbout DNA polymerase alpha
DNA polymerase alpha is a crucial enzyme involved in initiating DNA replication in eukaryotic cells. It plays a fundamental role in DNA synthesis, making it essential for cell proliferation and a potential target for therapeutic intervention.
Currently, there is no genetic evidence directly linking DNA polymerase alpha to specific diseases. However, its fundamental role in DNA replication makes it a relevant target for drug development, particularly in areas where controlling cell proliferation is desired.
One FDA-approved drug, Fludarabine Phosphate, targets DNA polymerase alpha as a small molecule. This drug, marketed by Hikma, highlights the potential of targeting this enzyme, particularly in therapeutic areas such as cancer.
Top DNA polymerase alpha Drugs
Hikma is the only company with an approved drug targeting DNA polymerase alpha.
Low competition suggests a potential market opportunity for new entrants.
DNA polymerase alpha Clinical Trials 927 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on DNA polymerase alpha. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 550 | 136 | 129 | 272 | 51% |
| Phase 2 | 326 | 107 | 94 | 123 | 53% |
| Phase 3 | 46 | 17 | 6 | 23 | 74% |
| Phase 4 | 5 | 3 | 2 | 0 | 60% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 256 (76 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on DNA polymerase alpha. A trial counts if an approved drug acting on DNA polymerase alpha is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.